Inmular Approved as First Domestically Developed Long Acting RSV Prophylactic Monoclonal Antibody in China
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
Simcere Announces Strategic Partnership with Reyoung Bio to Secure Exclusive Commercialization Rights for Long-Acting RSV Monoclonal Antibody
Cosela? Receives Approval for a New Indication, Expanding Full-Cycle, Multi-Lineage Myeloprotection Across All Chemotherapy Lines for Extensive-Stage Small Cell Lung Cancer
Simcere and Schr?dinger Enter Global Drug Discovery and Development Collaboration
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
Simcere Zaiming Announces First Patient Enrolled in Phase I Clinical Trial of Anti-LRRC15 ADC SIM0613
Simcere Zaiming Presents 9 Studies at the 2026 ASCO Annual Meeting
Simcere Zaiming’s Pan-RAS Inhibitor SIM0532 Doses First Patient in Clinical Trial
Simcere Zaiming’s LRRC15-Targeting ADC SIM0613 Receives IND Approval in China
Telephone: 025-85566666 Fax：025-85262330
Address: 699-18 Xuanwu Avenue Nanjing China
Zipcode：210042
Fax：025-85471729
Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345 Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate) ? Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.